BICYCLE PHARMACEUTICALS PUBLICATIONS INVESTORS & MEDIA CONTACT US About Approach Programs Beyond Oncology Patients Careers Patients Our mission is to make a life-changing impact to help patients with cancer and other diseases. Commitment Cancer is one of the greatest health threats of our time. According to the World Health Organization International Agency for Research on Cancer, in 2018, there were an estimated 17.0 million cases of cancer diagnosed around the world and 9.5 million cancer deaths. At Bicycle, our mission is to generate significant patient benefit by creating breakthrough medicines designed to transform the treatment paradigm for cancer. The uniqueness of Bicycle’s proprietary technology allows us to design and develop versatile and innovative medicines to target cancer. While excellent progress has been made in the development of new cancer therapeutics, most patients with metastatic disease remain incurable. Bicycle’s therapeutic focus is to develop new therapies for patients with the most aggressive cancers, such as pancreatic, triple negative breast cancer, lung cancer and gastric cancer. In addition, several less common tumors such as sarcomas, gastric or head and neck cancers, as well as orphan tumors, continue to have few options for therapy, and only some of those tumors respond to current therapeutic approaches. We are committed to improving the lives of patients with these difficult to treat tumors. Cancer Research UK Partnership We have partnered with Cancer Research UK (CRUK), the world’s largest cancer charity and a leading research organization, to rapidly advance our lead Bicycle Toxin Conjugate candidate BT1718 for the treatment of patients with advanced solid tumors and one of our immuno-oncology candidates, BT7401, a multivalent Bicycle CD137 agonist. CRUK has an impressive track record of discovering and developing novel treatments for cancer, with the organization’s Centre for Drug Development having taken more than 140 agents into early clinical trials. Six of these are now marketed drugs. These collaborations provide Bicycle with access to CRUK’S extensive oncology expertise and broad network of clinical investigators. CRUK is funding and sponsoring a Phase IIa clinical trial for BT1718 and will fund a Phase I/IIa trial for BT7401 (now in preclinical development). Bicycle retains the right to further advance both assets beyond Phase IIa studies. Privacy Policy Contact © Bicycle Therapeutics